196 related articles for article (PubMed ID: 26170629)
1. Siltuximab (CNTO 328): a promising option for human malignancies.
Chen R; Chen B
Drug Des Devel Ther; 2015; 9():3455-8. PubMed ID: 26170629
[TBL] [Abstract][Full Text] [Related]
2. Siltuximab: a new option for the management of Castleman's disease.
Barquero N
Drugs Today (Barc); 2015 Jan; 51(1):21-8. PubMed ID: 25685858
[TBL] [Abstract][Full Text] [Related]
3. Siltuximab for multicentric Castleman disease.
Liu YC; Stone K; van Rhee F
Expert Rev Hematol; 2014 Oct; 7(5):545-57. PubMed ID: 25110138
[TBL] [Abstract][Full Text] [Related]
4. The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study.
Karkera J; Steiner H; Li W; Skradski V; Moser PL; Riethdorf S; Reddy M; Puchalski T; Safer K; Prabhakar U; Pantel K; Qi M; Culig Z
Prostate; 2011 Sep; 71(13):1455-65. PubMed ID: 21321981
[TBL] [Abstract][Full Text] [Related]
5. CNTO-328 (Centocor).
Li J; Hu XF; Xing PX
Curr Opin Investig Drugs; 2005 Jun; 6(6):639-45. PubMed ID: 15988916
[No Abstract] [Full Text] [Related]
6. Siltuximab and hematologic malignancies. A focus in non Hodgkin lymphoma.
Ferrario A; Merli M; Basilico C; Maffioli M; Passamonti F
Expert Opin Investig Drugs; 2017 Mar; 26(3):367-373. PubMed ID: 28140696
[TBL] [Abstract][Full Text] [Related]
7. A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer.
Rossi JF; Négrier S; James ND; Kocak I; Hawkins R; Davis H; Prabhakar U; Qin X; Mulders P; Berns B
Br J Cancer; 2010 Oct; 103(8):1154-62. PubMed ID: 20808314
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic and pharmacodynamic modeling of an anti-interleukin-6 chimeric monoclonal antibody (siltuximab) in patients with metastatic renal cell carcinoma.
Puchalski T; Prabhakar U; Jiao Q; Berns B; Davis HM
Clin Cancer Res; 2010 Mar; 16(5):1652-61. PubMed ID: 20179212
[TBL] [Abstract][Full Text] [Related]
9. Siltuximab: A Review in Idiopathic (Human Herpesvirus-8-Negative) Multicentric Castleman Disease.
Lyseng-Williamson KA
BioDrugs; 2015 Dec; 29(6):399-406. PubMed ID: 26394632
[TBL] [Abstract][Full Text] [Related]
10. Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer.
Fizazi K; De Bono JS; Flechon A; Heidenreich A; Voog E; Davis NB; Qi M; Bandekar R; Vermeulen JT; Cornfeld M; Hudes GR
Eur J Cancer; 2012 Jan; 48(1):85-93. PubMed ID: 22129890
[TBL] [Abstract][Full Text] [Related]
11. The effects of interleukin-6 neutralizing antibodies on symptoms of depressed mood and anhedonia in patients with rheumatoid arthritis and multicentric Castleman's disease.
Sun Y; Wang D; Salvadore G; Hsu B; Curran M; Casper C; Vermeulen J; Kent JM; Singh J; Drevets WC; Wittenberg GM; Chen G
Brain Behav Immun; 2017 Nov; 66():156-164. PubMed ID: 28676350
[TBL] [Abstract][Full Text] [Related]
12. A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease.
van Rhee F; Casper C; Voorhees PM; Fayad LE; van de Velde H; Vermeulen J; Qin X; Qi M; Tromp B; Kurzrock R
Oncotarget; 2015 Oct; 6(30):30408-19. PubMed ID: 26327301
[TBL] [Abstract][Full Text] [Related]
13. Clinical development of siltuximab.
Davis CC; Shah KS; Lechowicz MJ
Curr Oncol Rep; 2015 Jul; 17(7):29. PubMed ID: 25986720
[TBL] [Abstract][Full Text] [Related]
14. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers.
Yao X; Huang J; Zhong H; Shen N; Faggioni R; Fung M; Yao Y
Pharmacol Ther; 2014 Feb; 141(2):125-39. PubMed ID: 24076269
[TBL] [Abstract][Full Text] [Related]
15. JAK1 Genomic Alteration Associated With Exceptional Response to Siltuximab in Cutaneous Castleman Disease.
Patel M; Ikeda S; Pilat SR; Kurzrock R
JAMA Dermatol; 2017 May; 153(5):449-452. PubMed ID: 28241173
[TBL] [Abstract][Full Text] [Related]
16. Siltuximab (Sylvant) for treatment of multicentric castleman's disease.
Med Lett Drugs Ther; 2015 Jan; 57(1459):e8. PubMed ID: 25555075
[No Abstract] [Full Text] [Related]
17. Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease.
Casper C; Chaturvedi S; Munshi N; Wong R; Qi M; Schaffer M; Bandekar R; Hall B; van de Velde H; Vermeulen J; Reddy M; van Rhee F
Clin Cancer Res; 2015 Oct; 21(19):4294-304. PubMed ID: 26124203
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-6 as a therapeutic target in human ovarian cancer.
Coward J; Kulbe H; Chakravarty P; Leader D; Vassileva V; Leinster DA; Thompson R; Schioppa T; Nemeth J; Vermeulen J; Singh N; Avril N; Cummings J; Rexhepaj E; Jirström K; Gallagher WM; Brennan DJ; McNeish IA; Balkwill FR
Clin Cancer Res; 2011 Sep; 17(18):6083-96. PubMed ID: 21795409
[TBL] [Abstract][Full Text] [Related]
19. Regulation of growth of prostate cancer cells selected in the presence of interleukin-6 by the anti-interleukin-6 antibody CNTO 328.
Steiner H; Cavarretta IT; Moser PL; Berger AP; Bektic J; Dietrich H; Zaki MH; Nakada M; Hobisch A; Nemeth JA; Culig Z
Prostate; 2006 Dec; 66(16):1744-52. PubMed ID: 16998813
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-6: an angiogenic target in solid tumours.
Middleton K; Jones J; Lwin Z; Coward JI
Crit Rev Oncol Hematol; 2014 Jan; 89(1):129-39. PubMed ID: 24029605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
